EICHORPublic-registry site landscape for NCT02128282, “Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma”, a Cholangiocarcinoma study sponsored by Senhwa Biosciences, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02128282 (registry record) |
| Study title | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma |
| Official title | A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma |
| Sponsor | Senhwa Biosciences, Inc. |
| Condition(s) | Cholangiocarcinoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 16 |
| Site countries | United States, South Korea, Taiwan |
Patient-friendly overview of this study: eichor.com/study/NCT02128282.
Eichor generates a preliminary site-risk snapshot for NCT02128282 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Cholangiocarcinoma trials
← Eichor home · All tracked trials · Cholangiocarcinoma studies · Weekly briefs
